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Abstract
Targeted delivery aims to selectively distribute drugs to targeted tumor tissue but not to healthy 
tissue. This can address many of clinical challenges by maximizing the efficacy but minimizing 
the toxicity of anti-cancer drugs. However, complex tumor microenvironment poses various 
barriers hindering the transport of drugs and drug delivery systems. New tumor models that allow 
for the systematic study of these complex environments are highly desired to provide reliable test 
beds to develop drug delivery systems for targeted delivery. Recently, research efforts have yielded 
new in vitro tumor models, the so called tumor-microenvironment-on-chip, that recapitulate 
certain characteristics of the tumor microenvironment. These new models show benefits over other 
conventional tumor models, and have the potential to accelerate drug discovery and enable 
precision medicines. However, further research is warranted to overcome their limitations and to 
properly interpret the data obtained from these models. In this article, key features of the in vivo 
tumor microenvironment that are relevant to drug transport processes for targeted delivery was 
discussed, and the current status and challenges for developing in vitro transport model systems 
was reviewed.
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1. Introduction
Many promising anti-cancer drug candidates have been identified in the last several decades. 
However, only a handful have exhibited therapeutic efficacy on human patients. This is 
largely due to the limited delivery of drugs to target tumors, which can result in unwanted 
accumulation of compounds to non-targeted healthy tissues and organs, and ultimately to 
systemic toxicity. Targeted delivery, which aims to selectively distribute drugs to targeted 
tumor tissue but not to healthy tissue, can address many of these difficulties. Such targeted 
delivery, however, is very difficult to achieve [1]. Thus, the term “targeted” is used in this 
article refers to the preferential delivery of drugs to the tumor site. It should be distinguished 
from “targeted therapy” which refers to drugs interfering with specific molecular targets in 
cancers.
Recent developments in the field of nanotechnology enables the synthesis of a wide variety 
of nanoparticles (NPs), whose size and surface properties can be designed to serve as 
effective vehicles for targeted delivery. These nanostructures include liposomes, polymer 
micelles, dendrimers, drug nanocrystals, magnetic nanoparticles, gold nanoparticles/
nanoshells, nanorods, nanotubes, and drug-polymer conjugates (all of which will be 
collectively referred to as NPs). Research aimed at controlling the size and surface 
properties of these NPs to be responsive to the tumor microenvironment has been performed 
as reported elsewhere [2-5]. Even though improvements in the delivery efficacy have been 
shown, the majority of administered NPs fail to reach target tumors. One of the biggest 
benefits of using NP formulations is to avoid non-aqueous solvents for administering 
hydrophobic drugs to patients, resulting in fewer side effects, while maintaining the same 
efficacy. The success of Abraxane® (nanoparticle albumin-bound paclitaxel) and Doxil® 
(PEGylated liposome formulation), in large part, relies on delivering anticancer drugs 
without using organic solvents. In order to maximize the therapeutic outcomes, however, 
drug accumulation as well as penetration into the targeted tumors should be improved. The 
challenge before us is to achieve effective delivery to the cancer cells since it is significantly 
hindered by various barriers engendered by the complex tumor microenvironment (TME).
After being administered into a patient's blood stream, the drugs (for brevity, the term “drug” 
is used to refer both drug and drug delivery system including NPs) are thought to be 
subjected to complex and multi-faceted transport processes prior to reaching the cancer cells 
as reviewed previously [6-10]. These include – i) blood flow-driven transport to the tumor 
vasculature, ii) transvascular transport (i.e., extravasation), iii) interstitial transport, and iv) 
cellular uptake and metabolism as illustrated in Figure 1. Excess drugs often occupy the 
interstitial space or are transported through the lymphatic vessels. These transport 
phenomena are governed by diffusion and convection processes, and the significance of each 
process is dependent on both drugs and the biophysical conditions of TME. The drug 
dependent properties are the size and surface properties, and the TME dependent ones 
include leakiness of the blood vessel wall, interstitial fluid pressure gradient, and the 
extracellular matrix (ECM) microstructure within the tumor interstitium. These processes 
and physiological conditions are highly dynamic, interconnected and vary spatiotemporally.
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Besides these biophysical barriers, the TME also poses biochemical and biological 
complexities. Typically, tumor tissues consist of cancerous cells as well as stromal 
components that consist of various stromal cells including cancer-associated fibroblasts 
(CAF), diverse immune and inflammatory cell types and rich extracellular matrix 
components, such as type I collagen [11, 12]. In addition to the highly heterogeneous cancer 
cell populations, i.e. intra-tumoral heterogeneity, the complex stromal tissue acts as a 
repository for various growth factors and cytokines that can dramatically influence tumor 
growth and drug response, as well as creating a hypoxic environment. Thus, it is important 
to understand the TME to design and develop effective targeted drug delivery systems. New 
tumor models that allow for the systematic study of these complex environments are highly 
desired and will provide reliable test beds to characterize and optimize the design of drugs.
Several tumor models are available but they do not adequately address this challenge. 
Conventional static in vitro systems, including cell suspensions and cell monolayers, are not 
sufficient to study these complex in vivo transport processes because the model systems lack 
dynamic interactions among the cells, ECM, interstitial fluid and NPs. Animal models can 
provide a TME with all of these dynamic interactions, but such models are limited to 
systematically studying the effects of these dynamic interactions. Recently, research efforts 
have yielded new in vitro tumor models, the so called tumor-microenvironment-on-chip (T-
MOC), that recapitulate certain characteristics of the TME. Although various configurations 
have been developed, T-MOCs are basically microfluidic platforms where cancer cells are 
cultured within the ECM under perfusion conditions. These new models show benefits over 
other conventional tumor models, and have the potential to accelerate drug discovery and 
patient-specific personalized treatment planning. However, the TME is extremely complex 
and there remain significant limitations to overcome. In this article, key features of the in 
vivo TME that are relevant to drug transport processes for targeted delivery are reviewed, 
and the current status and challenges for developing transport model systems are discussed.
2. Tumor microenvironment: A complex and chaotic bed for tumor growth
The tumor microenvironment is a complex and adverse environment for drug transport and 
action. It comprises a highly heterogeneous mixture of tumor and stromal cells embedded in 
an extracellular matrix that also includes cytokines, growth factors, inflammatory cells and 
macrophages. Together, the TME poses multi-faceted barriers including biological, chemical 
and physical hindrances to drug transport and actions. These barriers are highly dynamic and 
often interconnected. Their interactions and relative significance with respect to drug 
delivery and therapeutic efficacy vary drastically depending on the cancer type, stage and 
organs. The current difficulty in developing new anticancer drugs and drug delivery systems 
partly stems from the lack of a clear understanding of the delicate interplay of these barriers 
at the TME [13-15]. Thus, instead of providing a generic description on these hindrances, it 
is more relevant to collectively discuss the interplays that are associated with one type of 
cancer. Here, our discussion will be focused on pancreatic cancer and its associated TME 
unless mentioned otherwise.
Pancreatic ductal adenocarcinoma (PDAC) is a significant clinical challenge due to its poor 
prognosis and extremely low (7%) five-year survival rate [16]. Its extensive TME presents 
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many key features relevant to discussing the hindrances and resistance of drug transport and 
actions. One of the most notable characteristics of PDAC is its marked desmoplasia. The 
desmoplastic stroma of PDAC is composed of CAFs, various immune and inflammatory cell 
types and a dense extracellular matrix [11, 12], as illustrated in Figure 1. Moreover, PDAC 
is poorly vascularized and has extremely high interstitial fluid pressure (IFP) [17-19]. In this 
complex 3D TME, highly intricate and multifaceted interactions occur among pancreatic 
cancer cells (PCC), CAFs, tumor-associated macrophages (TAMs) and other immune cells. 
The biochemical and biophysical interactions occurring among the cells within the TME are 
poorly understood.
PDAC is a complex, heterogeneous and genetically unstable disease which is caused by 
prolonged accumulation of mutations in key oncogenes and tumor suppressor genes 
[13,47,113]. These include activation of the Kras2 oncogene, inactivation of the tumor 
suppressor gene Cdkn2A/Ink4A, and finally, inactivation of the tumor suppressor genes 
TP53 and Dpc4/Smad4 [25,68]. Recent studies indicate that PCCs carry an average of 63 
genetic alterations per cancer, which can be grouped into 12 core signaling pathways [20]. 
PDAC is thought to arise from precursor lesions such as pancreatic intraepithelial neoplasia 
(PanIN). These lesions develop into invasive carcinoma through a multistep carcinogenic 
process (illustrated in Figure 2).
The complex TME of PDAC poses multiple barriers that inhibit transport and action of 
drugs. First, the TME serves as a biophysical barrier that impedes effective transport of 
drugs to target cancer cells or associated stromal cells. After administration, drugs are 
subject to complex transport processes to reach the cancer cells, including blood flow-driven 
transport, drug-endothelium interactions, extravasation, interstitial transport and cellular 
uptake [6, 7]. Although the drugs are thought to preferentially extravasate more in tumors 
than in normal tissues via the so called enhanced permeation and retention (EPR) effect [24, 
25], the hypovascularity of PDAC may limit the benefit of EPR effects [26, 27]. 
Nonetheless, a certain percentage of PDACs exhibit a strong angiogeneic gene signature and 
areas of increased microvessel density [28], raising the possibility that drug delivery may be 
more efficient in this patient subgroup. However, even after the drugs preferentially 
extravasate into the PDAC TME, the drugs encounter a very dense stroma and significantly 
elevated IFP. The dense stroma is attributed to activated CAF, inflammatory immune cells 
and an excessive deposition of a complex ECM that includes dense collagen type I and III 
bundles, hyaluronic acid, fibronectin and desmin [17, 18, 29], as illustrated in Figure 3. The 
dense ECM microstructure and cell packing of stromal tissue significantly hinders interstitial 
transport in conjunction with elevated IFP [18, 27, 30-33]. These features are compounded 
by hypoxia and infiltration of growth promoting inflammatory cells at the TME.
Second, increasing evidence has shown that various TME components, including the ECM, 
soluble cytokines, growth factors, the MMP family of proteases, and immunosuppressive 
and pro-tumorigenic immune cells, contribute to extensive tumor promoting properties. 
Pancreatic stellate cells are activated into CAFs, which produce and deposit fibronectin and 
collagens, whereas inflammatory cells and macrophages produce chemokines and cyokines. 
Thus, the TME of PDAC is rich in growth factors, including fibroblast growth factors 
(FGFs), epidermal growth factor (EGF) receptor ligands, transforming growth factor-β 
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(TGF-β) isoforms, and connective tissue growth factor (CTGF) [19, 34, 35]. These chemical 
environments facilitate not only stroma production, but also enhance PCC proliferation, 
epithelial-mesenchymal-transition (EMT), metastatic potential, and importantly, therapeutic 
resistance through molecular interactions between cancer cells and CAFs. The combination 
of these complex biochemical environments with hypoxia and heterogeneous genetic 
mutations makes PDAC incredibly resistant to therapeutics.
The development of genetically engineered mouse models (GEMMs) of PDAC has greatly 
aided fundamental studies of the interactions between PCCs and stromal cells. For example, 
PDAC CAFs express vitamin D receptors, and activation of these receptors by the calcitriol 
analogue suppresses deleterious immunological cell infiltrates in mouse PDAC (mPDAC) 
[36]. Conversely, CAF depletion in mPDAC has been associated with altered immune gene 
expression and altered infiltrating immune cell populations, including decreased CD4+ 
effector T cells, increased CD4+Foxp3+ regulatory T cells (Treg), and decreased cytotoxic 
CD8+/Treg and CD3+/CD11b+ ratios [37]. Ctla4 expression was also increased, meaning 
that treatment of CAF-depleted mice with a CLTA-4 blocking antibody attenuated PDAC 
progression, improved overall survival, induced tumor clearance in up to 25% of the 
pancreas, and reprogrammed the transcriptome to a pattern that resembled control (CAF-
competent) tumors. Similarly, deletion of Shh in cancer cells to suppress mPDAC stroma led 
to more frequent PanIN and ADM lesions at a young age, an earlier appearance of loss of 
differentiation of mPDAC, increased metastasis, and more rapid death [37]. There was also 
enhanced cancer cell proliferation and angiogenesis, increased Zeb1 and Slug expression 
consistent with EMT, and reduced CD45+ myeloid cells and F4/80+ monocytes infiltration. 
Similar results were observed when animals were treated with a Smoothened inhibitor. 
Genetic Shh deletion or pharmacological targeting of Shh signaling pathways attenuates 
stroma formation but leads to more aggressive mPDAC. Thus, depending on the strategy, 
stroma depletion can cause beneficial or deleterious effects in GEMMS of PDAC.
3. Transport barriers of TME and drug resistance
Pathophysiological characteristics of tumors present multiple levels of transport barriers to 
targeted delivery of drugs. These include leaky and chaotic vasculature of the tumor, 
increased IFP, less functional lymphatic vessels, dense ECM microstructure and high cell 
packing density [24, 25, 31-33], as illustrated in Figure 4A. These TME characteristics are 
highly dynamic, interconnected and vary spatiotemporally [13, 26], and the compounding 
effects of all of these physiological parameters on drug transport are not yet fully understood 
yet. In this section, the complex transport processes of how drugs reach to the targeted tumor 
will be discussed with relevant transport barriers posed by the TME.
Although it is not directly associated with TME, one of the most critical steps of drug 
transport is blood flow-driven transport. After being administered intravenously, the drugs 
first circulate in the blood stream consisting of complex cells and plasma proteins. During 
blood circulation, a significant portion of the drugs are taken up by the immune cells in the 
blood stream including monocytes, leukocytes, and dendritic cells; and in tissues by resident 
phagocytes, i.e., by the reticuloendothelial system (RES) of the spleen, liver, and lungs [38, 
39]. This clearance significantly reduces the amount of the drugs available in the blood 
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stream to reach their intended target. Thus, the surface of many drug delivery systems, 
particularly NPs, is PEGylated in order to decrease the uptake by the RES and prolong the 
circulation of the NPs [8, 38, 40]. Besides the uptake by the immune system, the NPs also 
interact with other components within the blood [40, 41]. These often can result in 
hemolysis, which refers to red blood cell destruction and degradation of NP integrity. 
Ultimately, this results in premature release of the encapsulated drugs.
Once the drugs reach the vicinity of their target site after escaping being cleared from the 
circulation, they are transported across the endothelium of the tumor vasculature to enter the 
tumor interstitium (i.e., extravasate). The tumor microvasculature is characterized by a 
highly disorganized network of blood vessels whose endothelium exhibit enlarged 
intercellular gaps, known as fenestrations, that are heterogeneously distributed across the 
tumor vasculature [43]. The size of these intercellular gaps, so called vascular pores, for 
different tumors have been reported to be between 300 and 700 nm, and in rare occasions 
can be up to 2 μm, which are significantly larger than those found within the normal tissue 
(typically smaller than 20 nm) [44-46]. These values should be interpreted with caution 
though, since many of these were measured using xenograft models and very limited 
information is available for human. Further research is warranted to validate whether these 
values are applicable to various cancer types, stages and organs in human patients.
Transvascular transport is thought to be extravasation of drugs by convection driven by the 
pressure gradient across this porous endothelium and diffusion by the concentration 
gradient. Thus, the transvascular permeability (i.e., measure of transvascular transport at a 
given set of pressure and concentration gradient) depends on the size of both the drugs and 
vascular pore. For small macromolecules with hydrodynamic diameters that are much 
smaller than the pore size, transvascular permeability is observed to be quite insensitive to 
the pore size [44]. However, for NPs that are larger in size, e.g. 50-200 nm, the effect of the 
pore size on transvascular permeability becomes more profound. Transvascular permeability 
also depends on the developmental state of the cancer. Transvascular permeability was found 
to be 2-fold greater in primary sites of breast cancer tumors (in the mammary fat) when 
compared to that at a metastatic sites, while the metastatic site was associated with a greater 
level of vascularization [47]. Yuan et al. [46] experimentally investigated the effect of 
molecular size on transvascular transport, and provided a transport property database of 
various molecules. Monsky et al. [48] illustrated that transvascular transport of 
macromolecules could be enhanced using vascular endothelial growth factor. Netti et al. [49, 
50] investigated transvascular transport enhancement by modulating tumor microvascular 
pressure using periodic or continuous injection of angiotensin II. Recently, a strategy to 
normalize the tumor vasculature to achieve improved drug delivery throughout the tumor 
tissue has been proposed [51, 52]. This approach aims to remodel the tumor vasculature to 
functional vasculature of the healthy tissues using antiangiogenic factors which bind to 
VEGF receptors of tumor-associated endothelial cells.
After extravasation, the drug transport through the tumor interstitial space against elevated 
tumor IFP and abnormal ECM structure [30, 33, 53]. IFP of a solid tumor stays at an 
elevated level and sharply decreases at the periphery of the tumor. Due to its importance 
during drug delivery, physiological changes by elevated tumor IFP have been studied by 
Han et al. Page 6
Cancer Lett. Author manuscript; available in PMC 2017 September 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
many researchers [32, 50, 53]. The IFP of various tumor types varies from 4 to 50mmHg 
with an approximate average of 20mmHg, which is much higher than the IFP of normal 
tissues, approximately 2mmHg [32, 54]. Drastically higher IFPs of 75~130 mmHg are 
reported for PDACs [18]. This elevated IFP is thought to result from anomalous 
characteristics of tumor vascular structure including high vascular permeability and the lack 
of a well-developed lymphatic system. The elevated IFP adversely affects the transport of 
therapeutic agents at several different levels - i) less extravasation of the agents and ii) 
radially outward interstitial fluid movement at the periphery of tumor [8]. Consequently, the 
elevated IFP contributes to insufficient delivery of drugs to the interior of tumors. Moreover, 
higher collagen content and consequent dense organization of collagen fibrils results in 
lower diffusivity of drugs. Thus, transport of drugs is significantly limited in the tumor 
interstitial space [33, 55-57]. A wide variety of methods have been proposed and 
investigated to enhance the interstitial transport, but the main underlying strategies are either 
lowering tumor IFP [58-60], or modulating tumor ECM structure [33, 61]. However, due to 
the complex interaction involving various physiological parameters, the control or 
manipulation of the tumor IFP and ECM structure still warrants further research.
Once the drugs are transported through the tumor interstitial space, these should act on 
tumor cells, but their efficacy may also be limited due to complete or partial drug resistance 
[62-65]. Multidrug resistance (MDR) is thought to be caused by a group of membrane 
proteins that extrude cytotoxic molecules, thus maintaining the intracellular drug 
concentration below effective levels. These proteins belong to the ATP binding cassette 
(ABC) superfamily of membrane transporters [66], most of which use the energy of ATP 
hydrolysis for the efflux of drugs (i.e. active transport). This family includes the well-
characterized P-glycoprotein (Pgp) encoded by the MDR-1 gene [67-72], the multidrug 
resistance protein (MRP) [73-77] and the mitoxantrone resistance protein (MXR), also 
known as the breast cancer resistance protein (BCRP) [78-80]. Numerous clinical data imply 
that MDR phenotypes in tumors are associated with the overexpression of these transporters. 
Since these transporters have wide recognition patterns of substrates, the overexpression of 
these proteins will result in multidrug resistance. In addition to the over-expression of these 
transporter proteins, cellular drug resistance also appears to be mediated by the binding of 
tumor cells to the ECM [81, 82].
The most extensively studied strategy for efficient drug delivery and efficacy is to inhibit 
drug efflux by modulating the activities of the MDR-associated proteins. This can be 
achieved by the co-application of MDR modulators with anti-cancer drugs. A wide variety 
of compounds have been identified as MDR modulators. For example, verapamil, 
cyclosporine and their derivatives have been investigated in preclinical studies and in some 
cases have resulted in increased intracellular drug concentration [83-85]. Besides these 
chemosensitizers, monoclonal antibodies have been studied as potential MDR modulators 
[86, 87]. In addition to the MDR-associated proteins, the membrane lipid has also been 
investigated as a target for manipulation, as reviewed elsewhere [88]. The alteration of 
membrane biophysical properties, including membrane fluidity and permeability, could 
increase or decrease cellular uptake of drugs [89-91]. Polymeric excipients [92] and 
transcriptional regulators [93] have also been studied. Although heat shock has been 
reported to induce MDR in some cancer cells [94, 95], an increase in cellular drug uptake 
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and cytotoxicity by ultrasound-induced hyperthermia was reported [96, 97]. Unfortunately, 
delivery of these modulators to the target tumor is as challenging as the drug delivery 
obstacles we face.
To achieve effective targeted drug delivery, various strategies have been proposed to exploit 
these pathophysiological characteristics of the TME. Currently, many drug delivery systems, 
primarily NP-based systems, are designed based on so-called “passive” and “active” 
targeting strategies, which rely on increased extravasation and ligand-receptor interactions, 
respectively [98]. The passive targeting is based on the fenestration and prolonged 
circulation by PEGylation. This is often called the EPR effects since it is caused by the 
increased vascular permeability of tumor vasculature [24, 25]. However, it has not been 
shown whether such EPR effect exists in human tumor. The term “active targeting” is used 
to describe a strategy to attach ligands on the surface of NPs so that the NPs selectively bind 
to the target tumor cells or endothelium. Clearly, active targeting becomes effective only 
after the NPs reach the vicinity of the target tumors. These strategies can result in improved 
accumulation of NPs at the tumor, but the in vivo efficacy of NPs and NP-mediated drug 
delivery is still significantly impaired [1, 10, 38]. Only about 5% of the administered dose 
ends up at the target tumors. Although this may be 5-fold increase compared with drug 
molecules, the remaining significant portion of the NPs is still taken up by the RES of the 
spleen, liver, and lungs as illustrated in Figure 4B.
4. Tumor models to simulate TME
Due to the multifaceted complexities of the TME ranging from molecular, genetic, and 
biological, to chemical and physical parameters, it is very difficult to interpret the efficacy 
and resistance of drugs and drug delivery systems. All TME parameters are highly dynamic, 
interconnected and vary spatiotemporally, and may adversely affect the extravasation and 
interstitial transport of drugs and the subsequent action [13, 26]. In order to achieve effective 
treatment, both drug and delivery system should be designed to properly transport through, 
and act on, target cells in this complex environment. One critical bottleneck to developing 
effective targeted delivery systems is a limited quantitative understanding of the in vivo 
transport and action of drugs due to a lack of versatile models capable of rapid systematic 
study [7, 99].
Most widely used tumor models are two dimensional (2D) cell monolayers, often consisting 
of human cancer cell lines on a substrate. Although these cell lines are valuable tools, their 
2D culture environment does not mimic the TME. Thus, the outcome from traditional 2D 
cell cultures often fails to be indicative of in vivo or clinical outcomes. A growing number of 
studies reported that the physical, chemical and mechanical microenvironment of cancer 
cells significantly affects cellular behaviors [100-106]. These include changes in cell 
morphology, gene expression and drug responses. Moreover, interactions of cancer cells 
with other cell types, ECM molecules, and the interstitial fluid in TME, should be properly 
represented. In order to address these deficiencies, three-dimensional (3D) models including 
spheroids and engineered tissue scaffolds have been developed [107, 108]. The 3D 
microenvironment and architectural structure provided by these models induce cell 
morphology, signaling, and gene expression similar to in vivo TME.
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The simplest in vitro 3D tumor model is multicellular tumor spheroid, whereas tumor cells 
spontaneously aggregate and form spheroid structure [108-110]}. Spheroids can be prepared 
by several methods including hanging drop method, liquid-overlay cultures, and dynamic 
bioreactors. By handing drop method, cells are form spheroids within small droplets of cell 
suspensions (approximately 20 to 50 μL) [111]. Due to the surface tension, liquid can 
maintain droplets when the lid is inverted and cells settled at the bottom of the droplet, air-
liquid interface. Liquid-overlay culture prevents cell adhesion to the culture substrates to 
induce cells to adhere to each other and form aggregates. To prevent adhesion to the culture 
vessel, the surface can be coated with agarose, poly-2-hydroxyethyl methacrylate (poly-
HEMA), or Matrigel inducing cellular aggregations [110, 112]. Spheroids can also be 
formed by culturing in bioreactors, which can provide dynamic conditions preventing cell-
substrate contact and promoting cells to form aggregates by either stirring or rotating 
bioreactors [113]. Nonetheless, these are convenient and relatively simple techniques to 
simulate in vivo solid tumor. Cells within spheroids display cell-cell interactions and 
produce in vivo tumor-like biochemical responses compared to 2D cell culture. However, the 
lack of interstitial fluid dynamics, which is highly relevant to drug transport at TME, is one 
of the major limitations [114, 115].
A large number of studies have historically relied on mouse xenograft and allograft 
(heterotopic and orthotopic) tumor models to test the efficacy of anti-tumor cytotoxic agents 
against established cancer cell lines. Although these studies have advanced the field and our 
knowledge of tumor biology, they are not ideal approaches because the tumors and TME that 
develop have limited similarity to the human disease. A better approach is to utilize GEMMs 
that initiate cancer in the correct cell type and at the correct time, to generate a tumor that 
more closely recapitulates the human TME. However, it is still challenging to obtain 
mechanistic information regarding drug and NP transport and action in GEMMs. More 
detailed reviews on animal models used in pre-clinical drug testing can be found elsewhere 
[116]. The TME of the animal models has many key features that are lacking in 2D and 3D 
in vitro models. However, even animal models often fail to simulate human in vivo 
environments and to provide a mechanistic explanation of the in vivo behavior of NPs [99]. 
This is because of (i) the unknown scaling factors necessary to extrapolate from animal 
models to human subjects [117], (ii) the mismatch between human cancer cells and mouse 
matrix environments [118, 119], (iii) the difficulties to simulate the heterogeneity of tumor 
microenvironmental parameters [120, 121], and (iv) the inability to independently control 
these parameters in GEMMs. Thus, a new model system is greatly desired, in which the 
TME parameters can be systematically and independently controlled, but at the same time 
the dynamic interactions among the fluids, ECM, cells and NPs are maintained.
In order to address the limitation of in vitro static cell culture and mimic a more in vivo-like 
environment, various new cancer cell cultures on microfluidic platforms have been 
developed as reviewed elsewhere [122-124]. Since this review is focused on drug transport 
at TME, several models relevant to study drug transport and action are presented in Figure 
5. Most of them are based on microfluidic technology and often called “tumor-on-chip” or 
“tumor-microenvironment-on-chip.” Although not shown, first generation microfluidic 
cancer cell cultures were 2D cell monolayers cultured on microchannels in the presence of 
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fluid flow exerting shear stress on the cells [125, 126]. Specifically, endothelial cells were 
cultured on a microfluidic channel where shear stress was applied at controlled manner to 
study the morphological changes in vitro [125]. Epithelial transport characteristics of 
multiple chemical compounds were also studied under both temporal and spatial chemical 
gradients [126]. The presence of cell-fluid interaction was a significant advance from the 
conventional 2D cell monolayer models, but the lack of 3D environment was the major 
limitation to be addressed since the cell physiology of 2D models is distinctively different 
from that of cells cultured in 3D matrices. To address this, 3D culture environments have 
been created by combining tumor spheroids and tissue engineering technology.
First, tumor spheroid models have been scaled up into a 384-well format hanging drop 
culture plate for high throughput assay of drug sensitivity as illustrated in Figure 5A [127]. 
This model significantly increased the throughout of screening of drug sensitivity for a given 
spheroid types, and also reported the differences in the drug response when the same types 
of cells were cultured in either 2D or spheroid format. In order to address the lack of 
interstitial fluid dynamics, recent studies tried to integrate spheroids into microfluidic 
platforms where spheroids were subject to interstitial fluid flow [128-130]. In these models, 
cancer cells or spheroids were cultured within polymeric matrices to mimic cell-matrix 
interactions in vivo, allowing for the generation of spatial gradients of growth factors and pH 
[100, 128, 131-135]. As illustrated in Figure 5B, Walsh et al. [128] reported that pH 
gradient of the perfused spheroid culture on a microfluidic platform, and visualized the 
doxorubicin diffusion through the tumor spheroids. However, this model was still limited to 
mimic elevated IFP, which is one of the key features of TME.
Although the interstitial fluid flow has been known to hinder drug transport as well as to 
affect the morphology and migration of cells, it is very difficult to recreate within in vitro 
tumor models, even in microfluidic platforms. Polacheck et al [136] developed a 
microfluidic platform to mimic stable pressure gradients and fluid flow across tumor 
interstitium as shown in Figure 5C. In this model, breast cancer cells (MDA-MB-231) were 
seeded in type I collagen matrix and cultured under the perfusion of interstitial fluid flow 
created by pressure difference across the matrix. By controlling the pressure of each media 
channel, the flow rate could be precisely controlled and its effects on cell migration behavior 
were studied. Cell migration relevant to metastasis and angiogenesis has also been studied 
using microfluidic platforms [137, 138]. In addition, a microfluidic platform has been 
proposed to mimic hypoxia [139].
All of these 3D tumor models show great promise for mimicking the in vivo TME, and 
ultimately engineered tumors [140, 141]. The most significant advantages of these 
microfluidic 3D models are flexibility and controllability to systematically study the effects 
individual TME parameters. However, microfluidics models still warrant further research to 
create directional cell-matrix and tissue-tissue interactions [142]. Since cells are typically 
seeded within polymeric scaffolds in these 3D models, their cell-matrix interactions are non-
directional and this can greatly affect cell polarity differently from in vivo circumstances 
during cancer development [107, 143, 144]. Moreover, drug transport in vivo is greatly 
affected by the interfacial phenomena at the tissue-tissue interface, including endothelium-
blood, endothelium-interstitium, and interstitium-lymphatics endothelium. These 
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interactions need to be present in the model in order to properly simulate the drug transport 
in vivo.
As shown in Figure 5D, a T-MOC platform has been developed to recapitulate the complex 
and multiple transport processes in the TME [145]. Rather than mimicking a whole solid 
tumor, this platform was designed to recapitulate tumor tissue placed between capillary and 
lymphatic vessels. It had a 3D structure formed by stacking two PDMS layers of 
microchannels with a porous membrane inserted between the layers. Endothelial cells were 
cultured on the porous membrane to mimic the endothelium of the capillary. Along the 
capillary channel, drug-suspended medium flowed at physiologically relevant velocity and 
pressure. After extravasation, drugs entered the center channel of the bottom layer, which 
simulates the tumor interstitium. In this tumor channel, cancer cells were cultured within a 
3D collagen matrix, and the interstitial fluid flowed through the matrix and exerted elevated 
IFP. Then, the drugs were transported through this 3D tissue structure to reach the cancer 
cells, and remaining drugs might be drained to two side channels mimicking the lymphatics. 
Using this T-MOC platform, the transport of NPs and the effects of various TME parameters 
on the transport were systematically studied, including the vascular pore size, IFP, and 
collagen content and cell packing density of tumor tissue.
Although many epithelial tumors including PDAC and ductal carcinoma in situ (DCIS) 
originate from round epithelial duct where malignant cells acquire invasive properties and 
disrupt normal epithelial duct geometry. A T-MOC to mimic this directional cell-cell and 
cell-matrix interactions is shown in Figure 5E [146]. A lumen structure was generated along 
the microfluidic channel using a fluid dynamic phenomenon called “viscous fingering” 
[147]. First, collagen solution was filled along the microchannel and then culture medium 
droplets were placed at the inlet port to initiate the viscous fingering. As the lumen formed, 
the microfluidic chip was incubated to polymerize the collagen and fix the structure. Once 
the lumen structure was produced, cancer cells were seeded along the lining of the lumen by 
filling with cancer cell suspension. A micrograph of the cultured tumor with epithelial ductal 
geometry is shown.
5. Summary and conclusion
In order to achieve targeted drug delivery, the barriers posed by various aspects of the TME 
must be overcome to improve the delivery and efficacy of drugs. Identifying a molecular 
target for delivery systems is a good starting point, but it is not enough to guarantee efficient 
delivery. For example, to design targeted drug delivery systems, multifaceted aspects of 
TME should be considered including - i) the dense stroma, hypovascularity, and high IFP of 
the tumor which pose biophysical barriers to drug transport; ii) hypoxia, CAF-cancer cell 
interactions, and genetic instability which hinder the actions of drugs; and iii) substantial 
immunosuppression which present within the TME. These barriers are highly dynamic, 
interactive, and spatiotemporally vary during development, progression and treatment. Thus, 
a systematic study to establish quantitative knowledge of the effects of these parameters on 
the transport and action of drugs is a must. To mechanistically understand this complex 
environment, new tumor models are needed that provide systematic control of relevant 
parameters and rapid/high content analysis of multifaceted drug transport and actions.
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In this context, recent efforts to develop new in vitro tumor models such as T-MOC will 
provide a robust and convenient platform to rapidly screen various drug formulations, and to 
develop new targeted delivery strategies. Although these platforms have been developed to 
recapitulate the complex TME by culturing cancer cells with stroma cells within 3D 
extracellular matrices under perfusion, it is still not realistic, nor possible, to design a 
generic system to fully replicate every aspect of the TME. In order to maximize the benefit 
of these platforms, the model should be developed to test a specific hypothesis or certain 
aspects of TME while systematically varying biological, physical and chemical 
characteristics. Thus, rather than creating another step for drug discovery and screening, it 
can be used to obtain knowledge and insights, which can be extrapolated to drug design for 
animals and humans.
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Highlights
• Targeted delivery aims to selectively distribute drugs to targeted tumor 
but not to healthy tissue.
• Targeted delivery is very difficult to achieve due to transport barriers 
engendered by tumor microenvironment.
• Tumor microenvironment comprises a heterogeneous mixture of tumor 
and stromal cells embedded in an extracellular matrix.
• New in vitro tumor models based on microfluidic technology have been 
developed to recapitulate the complex transport in the tumor 
microenvironment.
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Figure 1. Complexity of the tumor microenvironment
TME poses multi-faceted barriers to drugs transport owing to the dense stromal tissue which 
is composed of collagens, fibronectin, and hyaluronan, an abundance of cancer-associated 
fibroblasts, and aberrant interactions between infiltrating tumor-associated immune cells, 
cancer cells, and CAFs.
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Figure 2. Schematic model of genetic alterations and histological examples of acinar cells, ADM 
(acinar-ductal metaplasia), PanIN, and PDAC progression as observed in a mouse model of 
PDAC
Diagram adapted from Morris et al. [21]. Images from Zhu et al. [22] and Shi et al. [23].
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Figure 3. Stromal components in PDAC and PanIN
(A, B) Mouse PDAC from elastase-CreERT2/LSL-KrasG12D/+/LSL-Tp53R172H/+/R26mTmG/+ 
mice. Upon tamoxifen treatment, CreERT2 becomes active in the acinar cell compartment, 
leading to activation of KRASG12D, TP53R172H and mGFP expression. In (B) membrane 
localized tdTomato Red (mT) labels stromal cells whereas membrane localized GFP (mG) 
marks the tumor epithelial cells. The majority of PDAC tumor mass consists of stromal 
components (indicated by asterisks in A and shown in red in B). (C, D) Mouse PanIN 
lesions from elastase-CreERT2/LSL-KrasG12D/+/LSL-Tp53R172H/+ mice. Sirius Red staining 
identifies extensive collagen deposition in (C). Similarly, anti-smooth muscle actin (SMA) 
(brown stain) identifies cancer associated fibroblasts (CAFs) surrounding the transformed 
PanIN epithelial cells in PDAC samples (D). (E, F) Human PDAC and PanIN H&E stained 
sections. The predominant stromal components are noted.
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Figure 4. Transport barriers at the tumor microenvironment, and the outcome of typical 
targeted delivery
(A) Schematic of vascular and tissue structure relevant to drug transport of normal and 
tumor tissues. In normal tissue, the endothelium is tightly packed and very low interstitial 
fluid flow presents. This fluid flows to the lymphatics through the normal ECM, and the IFP 
minimally builds up. On the contrary, the endothelium of tumor tissue is leaky and has large 
pores, which leads to high interstitial fluid flow and more extravasation of the NPs. In 
conjunction with less functional lymphatics and the dense ECM, this increased interstitial 
fluid flow results in elevated IFP, which adversely affects the extravasation. The 
compounding effects of the elevated IFP, leaky vasculature, and poor vascularization of the 
tumor are still not fully understood. Images from Ref [7]. (B) Relative NPs distribution at a 
target tumor site. Various NP-mediated drug delivery strategies have been reported to 
improve the drug accumulation at the intended target up to 5-fold increase. However, the 
majority of the administered drug ends up at non-targeted sites. Adapted from Ref [42].
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Figure 5. Recent development of in vitro tumor models
(A) Illustration of a high throughput hanging drop spheroid culture array plate, and its cross-
sectional view. (inset) Cartoon of the hanging drop formation and a spheroid [127]. (B) A 
microfluidic platform to culture tumor cells capable of monitoring cell growth, apoptosis, 
and pH [128]. (C) A tumor-on-chip platform to study the effects of interstitial fluid pressure 
gradient [136]. (D) A platform to mimic multiple transport processes at tumor vasculature 
and interstitium [145]. (E) A platform to mimic epithelial tumor growth and metastasis from 
circular lumen structure [146].
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